BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33428808)

  • 21. Survival from acute non-lymphocytic leukaemia (ANLL) and chronic myeloid leukaemia (CML) in European children since 1978: a population-based study.
    Gatta G; Luksch R; Coleman MP; Corazziari I;
    Eur J Cancer; 2001 Apr; 37(6):695-702. PubMed ID: 11311643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Epidemiological analysis of leukemia survival in Cracow for cases registered in 1980-1990].
    Fornal M; Janicki K; Grodzicki T
    Przegl Epidemiol; 2003; 57(4):671-82. PubMed ID: 15029843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
    Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloablative Unrelated Cord Blood Transplantation in Adolescents and Young Adults with Acute Leukemia.
    Hayashi H; Volt F; Sanz J; Petersen E; Dhedin N; Hough R; Milpied N; Angelucci E; Yakoub-Agha I; Michallet M; Michel G; Aljurf M; Kenzey C; Rocha V; Dalle JH; Bader P; Ruggeri A; Gluckman E;
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2438-2446. PubMed ID: 31394275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
    Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
    N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data.
    Mejía-Aranguré JM; Bonilla M; Lorenzana R; Juárez-Ocaña S; de Reyes G; Pérez-Saldivar ML; González-Miranda G; Bernáldez-Ríos R; Ortiz-Fernández A; Ortega-Alvarez M; Martínez-García Mdel C; Fajardo-Gutiérrez A
    BMC Cancer; 2005 Apr; 5():33. PubMed ID: 15807901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries.
    Bonaventure A; Harewood R; Stiller CA; Gatta G; Clavel J; Stefan DC; Carreira H; Spika D; Marcos-Gragera R; Peris-Bonet R; Piñeros M; Sant M; Kuehni CE; Murphy MFG; Coleman MP; Allemani C;
    Lancet Haematol; 2017 May; 4(5):e202-e217. PubMed ID: 28411119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-year audit of the pediatric hematolymphoid disease management group at Tata Memorial Hospital.
    Narula G; Prasad M; Jatia S; Subramanian PG; Patkar N; Tembhare P; Shetty D; Khanna N; Laskar S; Shet T; Epari S; Kembhavi S; Shah S; Qureshi S; Gujral S; Banavali SD
    Indian J Cancer; 2017; 54(4):609-615. PubMed ID: 30082544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
    Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
    Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database.
    Qasrawi A; Gomes V; Chacko CA; Mansour A; Kesler M; Arora R; Wei S; Ramlal R; Munker R
    Leuk Res; 2020 Feb; 89():106301. PubMed ID: 31982153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
    Janeczko-Czarnecka M; Krawczuk-Rybak M; Karpińska-Derda I; Niedźwiecki M; Musioł K; Ćwiklińska M; Drabko K; Mycko K; Ociepa T; Pawelec K; Januszkiewicz-Lewandowska D; Ussowicz M; Rybka B; Ryczan-Krawczyk R; Kołtan A; Karolczyk G; Zaucha-Prażmo A; Badowska W; Kałwak K
    Adv Clin Exp Med; 2018 Jan; 27(1):91-98. PubMed ID: 29521048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in the understanding and treatment of pediatric leukemias.
    Maloney KW; Giller R; Hunger SP
    Adv Pediatr; 2012; 59(1):329-58. PubMed ID: 22789585
    [No Abstract]   [Full Text] [Related]  

  • 37. Trends in leukemia incidence and survival in the United States (1973-1998).
    Xie Y; Davies SM; Xiang Y; Robison LL; Ross JA
    Cancer; 2003 May; 97(9):2229-35. PubMed ID: 12712476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
    Di Felice E; Roncaglia F; Venturelli F; Mangone L; Luminari S; Cirilli C; Carrozzi G; Giorgi Rossi P
    BMC Cancer; 2018 Nov; 18(1):1069. PubMed ID: 30400842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
    Lejeune C; Tubiana N; Gastaut JA; Maraninchi D; Richard B; Launay MC; Sainty D; Sebahoun G; Carcassonne Y
    Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.